Trial reportBMC anesthesiology2026
Comparison of the efficacy of Dexmedetomidine versus Ketamine as an adjunct to Ropivacaine for Scalp nerve block during Awake craniotomy surgery- A Randomised Controlled Trial : Dexmedetomidine versus Ketamine as adjuvants to Scalp nerve block.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundScalp nerve block (SNB) is an established technique for effective analgesia during awake craniotomy, but its analgesic duration is limited when local anesthetics are used alone. Adjuvants such as dexmedetomidine and ketamine may enhance block efficacy, though direct comparative evidence remains limited.
methodsThis prospective trial randomized forty-six adult patients undergoing elective awake craniotomy to receive SNB with 0.5% ropivacaine with dexmedetomidine 1 µg/kg (Group RD, n = 23) or ketamine 0.5 mg/kg (Group RK, n = 23). The primary outcome was the time to request the first rescue analgesia. Secondary outcomes included onset of sensory blockade, postoperative pain scores, rescue analgesic consumption, hemodynamic variables, respiratory depression, psychosis, and time to discharge from the postoperative ward.
resultsThe time to first rescue analgesia was significantly longer in Group RK compared with Group RD (18.67 [17.08-19.00] vs. 14.67 [12.92-15.08] hours; P = 0.001). Group RK demonstrated significantly lower postoperative pain scores at 6,10, and 16 h postoperatively (P < 0.004) and reduced consumption of rescue analgesia (P < 0.001). The onset of sensory blockade was comparable with a higher incidence of respiratory depression in Group RD (P = 0.02). Group RK showed higher intraoperative heart rate and mean arterial pressure, though values remained within clinically acceptable limits.
conclusionKetamine (0.5 mg/kg) as an adjuvant to ropivacaine for SNB in awake craniotomy provides longer postoperative analgesia and reduced rescue analgesic requirements compared with dexmedetomidine, with a lower incidence of respiratory depression. Dexmedetomidine offers superior hemodynamic attenuation to noxious stimuli. Larger multicenter studies are warranted to establish optimal adjuvant selection. CLINICAL
trial registrationClinical Trials Registry-India (CTRI): CTRI/2024/01/061259, https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=OTY2NDQ=&Enc=&userName= Date of registration: 09/01/2024 Date of enrolment of first patient: 15/01/2024 Principal Investigator: Dr Ankur Luthra.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.